DUBLIN–(BUSINESS WIRE)–The “Diabetic
Macular Edema – Pipeline Review, H1 2019” drug pipelines has
been added to ResearchAndMarkets.com’s offering.
Diabetic Macular Edema – Pipeline Review, H1 2019
provides comprehensive information on the therapeutics under development
for Diabetic Macular Edema (Metabolic Disorders), complete with analysis
by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also
reviews of key players involved in therapeutic development for Diabetic
Macular Edema and features dormant and discontinued projects. The guide
covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and
Discovery stages are 6, 20, 8, 7, 41 and 2 respectively. Similarly, the
Universities portfolio in Preclinical and Discovery stages comprises 2
and 1 molecules, respectively.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Diabetic Macular Edema (Metabolic Disorders). -
The pipeline guide reviews pipeline therapeutics for Diabetic Macular
Edema (Metabolic Disorders) by companies and universities/research
institutes based on information derived from company and
industry-specific sources. -
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
undisclosed stages. -
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities. -
The pipeline guide reviews key companies involved in Diabetic Macular
Edema (Metabolic Disorders) therapeutics and enlists all their major
and minor projects. -
The pipeline guide evaluates Diabetic Macular Edema (Metabolic
Disorders) therapeutics based on mechanism of action (MoA), drug
target, route of administration (RoA) and molecule type. -
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. -
The pipeline guide reviews latest news related to pipeline
therapeutics for Diabetic Macular Edema (Metabolic Disorders).
Reasons to Buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies. -
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage. -
Find and recognize significant and varied types of therapeutics under
development for Diabetic Macular Edema (Metabolic Disorders). - Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies. -
Plan mergers and acquisitions meritoriously by identifying key players
and it’s most promising pipeline therapeutics. -
Formulate corrective measures for pipeline projects by understanding
Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus
of Indication therapeutics. -
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope. -
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Key Topics Covered
- Introduction
- Diabetic Macular Edema – Overview
- Therapeutics Development
- Therapeutics Assessment
- Companies Involved in Therapeutics Development
- Drug Profiles
- Dormant Projects
- Discontinued Products
- Product Development Milestones
- Appendix
Companies Mentioned
- 3SBio Inc
- Abpro Corp
- Aciont Inc
- Acucela Inc
- Aerie Pharmaceuticals Inc
- Aldeyra Therapeutics Inc
- Allergan Plc
- Allgenesis Biotherapeutics Inc
- Ampio Pharmaceuticals Inc
- Araim Pharmaceuticals Inc
- Ascentage Pharma Group Corp Ltd
- Boehringer Ingelheim GmbH
- Cell Medica Ltd
- Celon Pharma SA
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Chiome Bioscience Inc
- Clearside BioMedical Inc
- Coherus BioSciences Inc
- Elasmogen Ltd
- Exonate Ltd
- EyeGate Pharmaceuticals Inc
- EyeGene Inc
- Eyevensys SAS
- F. Hoffmann-La Roche Ltd
- Formycon AG
- Gene Signal International SA
- Graybug Vision Inc
- Isarna Therapeutics GmbH
- Kalvista Pharmaceuticals Inc
- Kodiak Sciences Inc
- Kowa Co Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabion SA
- Momenta Pharmaceuticals Inc
- Novartis AG
- Ocular Therapeutix Inc
- Oculis SA
- OcuNexus Therapeutics Inc
- Ohr Pharmaceutical Inc
- Opthea Ltd
- Outlook Therapeutics Inc
- Oxurion NV
- Pfizer Inc
- PharmAbcine Inc
- Profarma
- Protheragen Inc
- Qilu Pharmaceutical Co Ltd
- Regeneron Pharmaceuticals Inc
- Rezolute Inc
- and more…
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ax62qj
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs, Endocrine
and Metabolic Disorders Drugs, Optical
Disorders Drugs